| 18778188 |
Nishio H, Ieko M, Nakabayashi T: New therapeutic option for thromboembolism--dabigatran etexilate. Ann Pharmacother. 2008 May;42(5):680-5. Epub 2008 Apr 15.
BACKGROUND: Thrombin plays a key role in blood coagulation and haemostasis; thus its inhibition has been identified as a reasonable target to block the coagulation cascade. Direct thrombin inhibitors are potential prophylactic agents for venous thromboembolism and arterial thrombosis, which often accompany operative procedures and cardiac disease, especially orthopedic surgery and atrial fibrillation, respectively. New orally available anticoagulant agents with a wide therapeutic window are keenly anticipated because warfarin and heparins have some disadvantages, and recent progress in pharmaceutical techniques has led to the development of orally administered direct thrombin inhibitors. Objectives: In this review, we discuss the usefulness of dabigatran etexilate as a new therapeutic option for preventing thromboembolism, including chemistry, pharmacokinetics, and pharmacodynamics, from the results of recent clinical studies. METHODS: We systematically focused on relevant published studies, as data from recent clinical studies were difficult to obtain owing to their ongoing status. CONCLUSIONS: Dabigatran etexilate is a promising new oral anticoagulant that offers greatly expanded therapeutic options for both patients and physicians. |
33(0,1,1,3) |